SCHEMBL5229665

SCHEMBL5229665

Cc1ccc(N2CCCN(C(=O)OC(C)(C)C)CC2)nc1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CKS1B P61024 2/20 0.60
SKP1 P63208 2/20 0.60
SKP2 Q13309 2/20 0.60
GPR119 Q8TDV5 4/20 0.53
DDB1 Q16531 1/20 0.52
CRBN Q96SW2 1/20 0.52
HRH3 Q9Y5N1 1/20 0.51
MAP4K4 O95819 1/20 0.51
RET P07949 2/20 0.50
HPGD P15428 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
KDM4E B2RXH2 1/20 0.49
POLB P06746 1/20 0.49
WNT3A P56704 1/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
PDE10A Q9Y233 1/20 0.48
PANK3 Q9H999 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1594238 0.95 GPR119 (0.57) CKS1BSKP1SKP2GPR119DDB1
Hydrochloric Acid SCHEMBL29020760 0.94 GPR119 (0.56) CKS1BSKP1SKP2GPR119DDB1
SCHEMBL22581684 0.87 MEN1 (0.59) CKS1BSKP1SKP2GPR119DDB1
SCHEMBL594028 0.87 CKS1B (0.59) CKS1BSKP1SKP2GPR119DDB1
SCHEMBL22581766 0.87 CKS1B (0.59) CKS1BSKP1SKP2GPR119DDB1
SCHEMBL6352769 0.87 CKS1B (0.59) CKS1BSKP1SKP2GPR119DDB1
SCHEMBL2395123 0.87 CKS1B (0.59) CKS1BSKP1SKP2GPR119DDB1
SCHEMBL5235251 0.86 CKS1B (0.58) CKS1BSKP1SKP2GPR119DDB1
SCHEMBL22581855 0.85 KDM4E (0.69) CKS1BSKP1SKP2HRH3HPGD
SCHEMBL15827745 0.85 PPARG (0.48) CKS1BSKP1SKP2GPR119DDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357187-A1 Inhibitors of Dihydroceramide Desaturase For Treating Disease CENTAURUS THERAPEUTICS 2023-11-09 US disclosed
EP-4201936-A1 HETEROAROMATIC RING COMPOUND AS RET KINASE INHIBITOR, AND PREPARATION AND USE THEREOF Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CN) 2023-06-28 EP disclosed
US-8198287-B2 Substituted heteroaryl pyridopyrimidone derivatives SANOFI-AVENTIS (FR) 2012-06-12 US disclosed
US-8198287-B2 Substituted heteroaryl pyridopyrimidone derivatives SANOFI-AVENTIS (FR) 2012-06-12 US disclosed
US-20090306088-A1 SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES SANOFI-AVENTIS (FR) 2009-12-10 US disclosed
US-20090306088-A1 SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES SANOFI-AVENTIS (FR) 2009-12-10 US disclosed
US-20070219234-A1 Thienopyridine Derivatives SANKYO COMPANY, LIMITED (JP) 2007-09-20 US disclosed
EP-1764367-A1 THIENOPYRIDINE DERIVATIVES Sankyo Company, Limited (JP) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306088-A1 SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES GSK3B, GSK3A, GSKIP CKS1B 87/4885SKP1 101/4885SKP2 214/4885
US-20230357187-A1 Inhibitors of Dihydroceramide Desaturase For Treating Disease CERS2, SMPD1, ASAH1 CKS1B 2401/4885SKP1 1927/4885SKP2 4063/4885
US-20070219234-A1 Thienopyridine Derivatives RASGRP1, NRAS, HRH3 CKS1B 464/4885SKP1 1341/4885SKP2 1664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.